SCHEMBL21704014

SCHEMBL21704014

CC(C)(C)OC(=O)N1CCN(c2cc(F)c3c(c2)OCC(N)C3)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
GPR119 Q8TDV5 8/20 0.40
ALK Q9UM73 1/20 0.40
PDK2 Q15119 1/20 0.40
DPP4 P27487 1/20 0.39
KDM4E B2RXH2 1/20 0.39
THRB P10828 1/20 0.39
MMP2 P08253 1/20 0.39
MMP13 P45452 1/20 0.39
MMP14 P50281 1/20 0.39
ADAMTS5 Q9UNA0 1/20 0.39
KIT P10721 1/20 0.39
PIK3CA P42336 1/20 0.38
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30059886 1.00 MAPT (0.42) MAPTALDH1A1LMNAGPR119ALK
SCHEMBL30061814 1.00 MAPT (0.42) MAPTALDH1A1LMNAGPR119ALK
SCHEMBL20732122 1.00 MAPT (0.42) MAPTALDH1A1LMNAGPR119ALK
SCHEMBL21685951 0.85 MAPK1 (0.37) MAPTALDH1A1
SCHEMBL20722626 0.85 MAPK1 (0.37) MAPTALDH1A1
SCHEMBL21685953 0.85 MAPK1 (0.37) MAPTALDH1A1
SCHEMBL20722688 0.83 JAK1 (0.39) GPR119DPP4
SCHEMBL20722417 0.83 JAK1 (0.39) GPR119DPP4
SCHEMBL21704068 0.83 CHRM2 (0.34) GPR119DPP4
SCHEMBL30060059 0.83 CHRM2 (0.34) GPR119DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112867712-B Carboxamide as ubiquitin-specific protease inhibitor 瓦洛早期发现股份有限公司 2024-07-16 CN disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 US disclosed
CN-112867712-A Carboxamides as ubiquitin-specific protease inhibitors 瓦洛早期发现股份有限公司 2021-05-28 CN disclosed
WO-2020033707-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2020-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 MAPT 2661/4885ALDH1A1 2167/4885LMNA 3132/4885
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP28, USP25, USP24 MAPT 2661/4885ALDH1A1 2167/4885LMNA 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.